BioCryst Pharmaceuticals, Inc.
BCRX
$9.81
$0.657.10%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 396.87% | 92.91% | 75.53% | 74.37% | 60.77% |
| Total Depreciation and Amortization | 15.80% | 19.36% | 13.61% | 9.72% | 5.06% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 13.03% | 4.04% | 4.34% | -20.47% | -24.73% |
| Change in Net Operating Assets | 34.81% | -25.25% | -23.57% | -89.42% | -169.38% |
| Cash from Operations | 767.76% | 190.08% | 120.05% | 74.48% | 45.32% |
| Capital Expenditure | -119.57% | -133.40% | 45.31% | 53.99% | 48.15% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -110.41% | 1,120.07% | 265.16% | 686.14% | 141.53% |
| Cash from Investing | -126.04% | 1,285.28% | 293.78% | 1,066.29% | 140.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -19,545.42% | -5,390.49% | -3,869.24% | 99.24% | 99.29% |
| Issuance of Common Stock | 126.02% | 101.14% | 118.76% | -10.08% | -53.25% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -223.12% | 10.48% | 16.03% | 82.30% | 78.21% |
| Cash from Financing | -5,974.14% | -2,668.00% | -1,429.71% | -115.87% | -117.73% |
| Foreign Exchange rate Adjustments | 235.68% | -95.73% | 364.73% | -222.88% | -358.56% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -144.71% | 75.65% | 114.38% | 129.45% | 96.84% |